MiniMed Group, Inc. Common Stock (MMED)

Newly spun-off diabetes-device pure-play with mid-teens revenue growth, ~55% gross margins and a net-cash balance sheet — but still loss-making on a trailing GAAP basis, burning free cash flow, carrying negative DCF values at a 105x EV/EBITDA multiple, and facing a just-expired lock-up on Medtronic's 90% stake plus a meaningful product-litigation tail. Fundamentals are weak-to-mixed with elevated risk: watchlist, not a buy, until the Flex/Fit launch trajectory shows up in GAAP earnings and cash flow.

Dominant near-term catalysts: the market-rewarded Q1 FY27 print (2026-09-01, announced — revenue beat, guidance raised, record high, analyst PT raises) versus the same-day 180-day lock-up expiry freeing ~90% Medtronic overhang — conflicting signals, moderate red-flag cap applied. Sentiment delta determinate at item level (moderate confidence): constructive in both windows with no deterioration; Reddit indeterminate; mixed, forming setup.

Chart quality in isolation would rate a 4: the Q1 FY27 earnings release (2026-09-01, +9.9%) and follow-through to the 52-week high of 24.43 (2026-09-02, +4.3%) on 4-6x average volume left price above SMA20/50/200 and EMA9/21 with ADX14 55.15 (very strong trend), MACD positive and expanding (line 1.36 vs signal 1.09), and a high-tight consolidation near the highs; the one weak signal is overbought momentum (RSI14 71.33, Williams %R -19.89) with tapering volume. The emitted score is capped at 2, not because of the chart, but because (a) fundamentals.fundamentalScore = 2 is a hard block (below the required floor of 3), and (b) this is a partial run with no run-date source (runDate absent from the stage envelope; company.cached=true; inherited currentDate 2026-09-09 untrusted), so per the run-date rule the read is treated stale-by-default and no chart or event window can be anchored honestly.